Antipodes Partners Exits Sanofi Position Over Pipeline Failures
Antipodes Partners sold its stake in Sanofi S.A., citing poor business development and concerns over the company's ability to handle Dupixent's loss of exclusivity.
Antipodes Partners exited its investment position in the French pharmaceutical company Sanofi S.A., according to the firm's second-quarter 2026 investor letter.
The investment firm attributed the decision to a series of pipeline disappointments. These setbacks reduced the firm's confidence in Sanofi S.A.'s ability to manage the upcoming loss of exclusivity for Dupixent, one of the company's key products.
Antipodes Partners further criticized Sanofi S.A.'s recent track record in business development, describing it as poor. The firm noted that any potential turnaround in research and development would likely be a multi-year endeavor.
Keep reading in the app
The full story and every source, free in the app.
Coming soonGoogle Play